Park Edge Advisors LLC Grows Stock Position in AbbVie Inc. $ABBV

Park Edge Advisors LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 57.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,253 shares of the company’s stock after buying an additional 3,394 shares during the period. Park Edge Advisors LLC’s holdings in AbbVie were worth $2,114,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie in the second quarter worth approximately $26,000. Chelsea Counsel Co. acquired a new position in AbbVie during the third quarter worth approximately $26,000. Westend Capital Management LLC acquired a new position in AbbVie during the fourth quarter worth approximately $29,000. Texas Capital Bancshares Inc TX purchased a new position in AbbVie during the third quarter worth approximately $31,000. Finally, Caitlin John LLC acquired a new position in shares of AbbVie in the 3rd quarter valued at $33,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Buying and Selling

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is owned by corporate insiders.

AbbVie Trading Down 2.9%

Shares of ABBV stock opened at $208.79 on Friday. The company has a market cap of $369.17 billion, a PE ratio of 88.47, a P/E/G ratio of 0.75 and a beta of 0.38. The company’s fifty day simple moving average is $221.79 and its 200-day simple moving average is $224.48. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the previous year, the firm posted $2.16 earnings per share. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie’s payout ratio is 293.22%.

Wall Street Analyst Weigh In

ABBV has been the subject of several research reports. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Morgan Stanley lifted their target price on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Barclays began coverage on AbbVie in a research note on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target for the company. Finally, Citigroup cut their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.